Literature DB >> 25043372

Probiotics in patients with severe acute pancreatitis.

Wan-Jie Gu, Jing-Chen Liu.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 25043372      PMCID: PMC4095728          DOI: 10.1186/cc13968

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.

Gou and colleagues have conducted a systematic review and meta-analysis of randomized controlled trials to determine the effects of probiotics in the treatment of severe acute pancreatitis [1]. We congratulate and applaud their important work, but several important issues should be noted. First, in the 'Methods' subsection of the Abstract, the authors stated 'Eligible studies were randomized controlled trials that compared the effects of probiotics administration with placebo treatment in patients with predicted SAP [severe acute pancreatitis]'. However, in Table two, the information for the Control group suggests that most of the eligible studies compared probiotics with control (that is, heat-inactivated L. plantarum 299 per serving, bioactive fibers, or water) rather than placebo. The two parts seem inconsistent. Second, in the 'Inclusion and exclusion criteria' subsection, the authors stated 'We included all human RCTs [randomized controlled trials] that investigated the effects of probiotics in SAP patients', but the trial of Plaudis and colleagues [2] was just a prospective feasibility study. Whether this study was a randomized controlled trial or not remains unclear, just as acknowledged by the authors in Table one. Strictly speaking, the Plaudis and colleagues trial should not be included. Third, in the 'Statistical analysis' subsection, the authors stated 'The Mantel-Haenszel random-effects model and fixed-effects model were used for data with and without significant heterogeneity, respectively'. What is the meaning of significant heterogeneity? I2 > 50% or something else? It is ambiguous and the authors need to clarify. Lastly, in Figure two, Besselink and colleagues [3] accounts for 69.9% (pancreatic infection), 81.2% (total infection), and 84.1% (mortality) of the total weight. The authors should perform sensitivity analysis by omitting the Besselink and colleagues trial to test the robustness of their results.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

WJG and JCL conceived the study, participated in the design, collected the data, and drafted the manuscript. All authors read and approved the final manuscript.
  3 in total

1.  Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.

Authors:  Marc Gh Besselink; Hjalmar C van Santvoort; Erik Buskens; Marja A Boermeester; Harry van Goor; Harro M Timmerman; Vincent B Nieuwenhuijs; Thomas L Bollen; Bert van Ramshorst; Ben Jm Witteman; Camiel Rosman; Rutger J Ploeg; Menno A Brink; Alexander Fm Schaapherder; Cornelis Hc Dejong; Peter J Wahab; Cees Jhm van Laarhoven; Erwin van der Harst; Casper Hj van Eijck; Miguel A Cuesta; Louis Ma Akkermans; Hein G Gooszen
Journal:  Lancet       Date:  2008-02-14       Impact factor: 79.321

2.  Early low volume oral synbiotic/prebiotic supplemented enteral stimulation of the gut in patients with severe acute pancreatitis: a prospective feasibility study.

Authors:  H Plaudis; G Pupelis; K Zeiza; V Boka
Journal:  Acta Chir Belg       Date:  2012 Mar-Apr       Impact factor: 1.090

Review 3.  Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Shanmiao Gou; Zhiyong Yang; Tao Liu; Heshui Wu; Chunyou Wang
Journal:  Crit Care       Date:  2014-03-31       Impact factor: 9.097

  3 in total
  1 in total

1.  Bacterial community mapping of the intestinal tract in acute pancreatitis rats based on 16S rDNA gene sequence analysis.

Authors:  Xufeng Tao; Fangyue Guo; Qi Zhou; Fenglin Hu; Hong Xiang; Gary Guishan Xiao; Dong Shang
Journal:  RSC Adv       Date:  2019-02-11       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.